 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Ionis Pharmaceuticals
IONS
conference date: October 29, 2025 @ 8:30 AM Pacific Time
Ionis: Price Slump Is An Opportunity To Buy The Pipeline [June 2, 2021, Seeking Alpha]
Ionis With Akcea: Still A Bargain [October 21, 2020 @ Seeking Alpha]
Ionis Is A Long On Neurological Medicines Pipeline [July 15, 2020 @ Seeking Alpha]
Ionis, Akcea Confirmation With Hypertriglyceridemia Results [January 28, 2020 @ Seeking Alpha]
older articles are below conference summary table
| 2025 | |||
| Ionis Q1 2025 |
Ionis Q2 2025 |
Ionis Q3 2025 |
|
| April 30, 2025 | July 30, 2025 | Oct. 29, 2025 | |
| 2024 | |||
| Ionis Q1 2024 |
Ionis Q2 2024 |
Ionis Q3 2024 |
Ionis Q4 2024 |
| May 7, 2024 | Aug. 1, 2024 | Nov. 6, 2024 | Feb. 19, 2025 |
| 2023 | |||
| Ionis Q1 2023 |
Ionis Q2 2023 |
Ionis Q3 2023 |
Ionis Q4 2023 |
| May 3, 2023 | Aug. 9, 2023 | Nov. 2, 2023 | Feb. 21, 2024 |
| 2022 | |||
| Ionis Q1 2022 |
Ionis Q2 2022 |
Ionis Q3 2022 |
Ionis Q4 2022 |
| May 4, 2022 | Aug. 9, 2022 | Nov. 9, 2022 | Feb. 22, 2023 |
| 2021 | |||
| Ionis Q1 2021 |
Ionis Q2 2021 |
Ionis Q3 2021 |
Ionis Q4 2021 |
| May 5, 2021 | Aug. 4, 2021 | Nov. 3, 2021 | Feb. 24, 2022 |
| 2020 | |||
| Ionis Q1 2020 |
Ionis Q2 2020 |
Ionis Q3 2020 |
Ionis Q4 2020 |
| May 6, 2020 | Aug. 5, 2020 | Nov. 4, 2020 | Feb. 24, 2021 |
| 2019 | |||
| Ionis Q1 2019 |
Ionis Q2 2019 |
Ionis Q3 2019 |
Ionis Q4 2019 |
| May 9, 2019 | August 7, 2019 | Nov. 6, 2019 | Feb. 26, 2020 |
2018 |
|||
| Ionis Q4 2018 |
|||
May 4, 2018 |
August 7, 2018 |
Nov. 6, 2018 |
Feb. 27, 2019 |
2017 |
|||
August 8, 2017 |
Nov. 7, 2017 |
Feb. 28, 2018 |
|
Ionis Hits Huntington's Milestone [February 1, 2019 @ Seeking Alpha]
Ionis Rising on RNA Therapy Optimism [December 14, 2018 @ Seeking Alpha]
Ionis is a Buy on RNA Platform Pipeline [March 7, 2018 @ Seeking Alpha]
Akcea Undervalued as Commercial Launches Near [April 12, 2018 @ Seeking Alpha]
Ionis Pharmaceuticals (IONS) is a biotechnology company specializing in RNA antisense based therapies, including Spinraza. Akcea Therapeutics (AKCA) is majority-owned by Ionis.
Ionis Pharmaceuticals web site
Ionis Pharmaceuticals investor relations
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CBIO |
| CDTX |
| CLDX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| RXRX |
| SAGE |
| SANA |
| VRTX |
| VSTM |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2025 William P. Meyers